BioSpace News Archive

Tempest Therapeutics, Inc. reported financial results for the year ended December 31, 2022 and provided a corporate update.

ScreenPro Security Inc. (CSE: SCRN) OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce the appointment of Alexander G. MacKay as its new Chief Executive Officer (CEO) and Chairman of the Company, effective March 23, 2023.

CytomX Therapeutics, Inc., a leader in the field of conditionally activated, localized biologics, announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets.

Eisai Co., Ltd. announced the company will present the latest findings on lecanemab, Eisai’s anti-amyloid beta protofibril* antibody for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders from March 28-April 1 in Gothenburg, Sweden and virtually.

Transcenta Holding Limited announces that two preclinical studies in relation to TST003, a First-in-Class mAb Targeting GREMLIN-1, and TST010, an ADCC enhanced anti-CD25 mAb will be presented as posters at the American Association for Cancer Research Annual Meeting 2023.

Transcenta Holding Limited announces the successful dosing of first patient in the U.S. Phase I Study of TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, for the treatment of solid tumors.

Biogen Inc. announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.

Ionis announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with superoxide dismutase 1 amyotrophic lateral sclerosis.